Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin in Advanced Solid Tumors
NCT03449381Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2018
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 1, open-label trial of brigimadlin in solid tumor (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 28 days, Progression-Free Survival at 24 months and 1 more. Started Jun 2018; status: completed.
02
Drugs
brigimadlin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03449381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03449381.